Ahumada-Del Castillo Syndrome
Ahumada-Del Castillo Syndrome
National Organization for Rare Disorders, Inc.
It is possible that the main title of the report Ahumada-Del Castillo Syndrome is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.
- Amenorrhea-Galactorrhea-FSH Decrease Syndrome
- Argonz-Del Castillo Syndrome
- Galactorrhea-Amenorrhea without Pregnancy
- Nonpuerperal Galactorrhea-Amenorrhea
Related Disorders List
Information on the following diseases can be found in the Related Disorders section of this report:
- Chiari-Frommel Syndrome
- Forbes-Albright Syndrome
Ahumada-Del Castillo is a rare endocrine disorder affecting adult females, which is characterized by impairment in the function of the pituitary and hypothalamus glands. Symptoms may include the production of breast milk (lactation) not associated with nursing and the absence of menstrual periods (amenorrhea) due to the lack of monthly ovulation (anovulation).
The symptoms of Ahumada-Del Castillo syndrome include the abnormal production of breast milk (galactorrhea) without childbirth and nursing, and the lack of regular menstrual periods (amenorrhea). Women with this disorder have breasts and nipples of normal size and appearance. Secondary female sexual characteristics, such as hair distribution and voice, are also normal. Since the ovaries do not produce eggs, affected females cannot become pregnant.
The exact cause of Ahumada-Del Castillo syndrome is not known, although some research suggests that small tumors in the pituitary or hypothalamus glands may be responsible for some cases. These tumors are frequently microscopic and extremely difficult to detect. Rarer causes of Ahumada-Del Castillo syndrome may be associated with low levels of thyroid hormone (hypothyroidism), chronic use of drugs that inhibit dopamine (antagonistics) (e.g., chlorpromazine or thorazine), and discontinuation of oral contraceptives (birth control pills). In all cases, an over-secretion of the milk-producing hormone prolactin (hyperprolactinemia) results in the symptoms of Ahumada-Del Castillo.
Ahumada-Del Castillo affects only females. The symptoms usually begin during adulthood.
Symptoms of the following disorders can be similar to those of Ahumada-Del Castillo syndrome. Comparisons may be useful for a differential diagnosis:
Chiari-Frommel syndrome is a rare endocrine disorder that affects females who have recently had a baby (postpartum). It is characterized by the production of breast milk (lactation), lack of ovulation (anovulation), and the absence of regular menstrual periods (amenorrhea) for more than 6 months. Other symptoms may include emotional distress, anxiety, headaches, backaches, abdominal pain, impaired vision, and/or obesity. (For more information on this disorder, choose "Chiari-Frommel" as your search term in the Rare Disease Database.)
Forbes-Albright syndrome is one in a group of rare endocrine disorders characterized by abnormally high levels of the hormone prolactin due to a tumor of the pituitary gland. Symptoms include the production and secretion of milk from the breasts (lactation) without associated childbirth or nursing (galactorrhea), and the absence of a regular menstrual period (amenorrhea). Women with Forbes-Albright syndrome generally have breasts and nipples of normal size and appearance, but the pattern of body hair and sexual drive may be reduced. (For more information on this disorder, choose "Forbes-Albright" as your search term in the Rare Disease Database.)
The diagnosis of Ahumada-Del Castillo Syndrome is usually made by specialized blood tests that detect abnormally elevated levels of the milk-producing hormone prolactin and low levels of the other hormones such as gonadotropins (e.g., follicle stimulating hormone or FSH).
The treatment of Ahumada-Del Castillo syndrome involves the administration of drugs that stimulate the production of dopamine (dopamine agonists) such as bromocriptine and perogolide. Two recently approved dopamine agonists, quinagolide and cabergoline, may be prescribed for women who do not respond to, or cannot tolerate, the commonly used bromocriptine.
All of these drugs lower the levels of prolactin and may stop abnormal milk secretion and restore normal menstrual periods.
The surgical removal of the small tumors of the pituitary and hypothalamus glands may be performed in some cases. In other patients, the tumors may respond to radiation therapy. When a disorder such as hypothyroidism causes Ahumada-Del Castillo syndrome, the symptoms are usually alleviated through the successful treatment of the underlying disorder. Other treatments may target specific symptoms.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government website.
For information about clinical trials being conducted at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
Goldman L, Ausielio D, eds. Cecil Textbook of Medicine. 22nd Ed. Philadelphia, PA. W. B. Saunders Co., 2003:1365-66.
Beers MH, Berkow R., eds. The Merck Manual, 17th ed. Whitehouse Station, NJ: Merck Research Laboratories; 1999:1066.
Berek JS, Adashi EY, Hillard et al. eds. 12th Ed. Novak's Textbook of Gynecology. Philadelphia, PA. Williams & Wilkins, 1996:351-57
Magalini SI, Magalini SC., eds. Dictionary of Medical Syndromes. 4th Ed. Philadelphia, PA. Lippincott Williams & Wilkins. 1999:44.
Losa M, Mortini P, Giovanelli M. A non-functioning pituitary adenoma initially mimicking a microprolactinoma: The case for long-term follow-up of patients with mild hyperprolactinemia. J Endocrinol Invest. 2005;28:367-70.
Biswas M, Smith J, Jadon D, et al. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf). 2005;63:26-31.
Verhelst J, Abs R. Hyperprolactinemia: pathophysiology and management. Treat Endocrinol. 2003;2:23-32.
Lamberts SW, Quik RF. A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia. J Clin Endocrinol. 1991;72:635-41.
Jones EE. Hyperprolactinemia and female infertility. J Reprod Med. 1989;34:117-26
National Women's Health Resource Center
157 Broad Street,
Red Bank, NJ 07701
National Women's Health Network
1413 K Street, NW
Washington, DC 20005
RESOLVE: National Infertility Association
1760 Old Meadow Rd
McLean, VA 22102
National Infertility Network Exchange
P.O. Box 204
East Meadow, NY 11554
Genetic and Rare Diseases (GARD) Information Center
PO Box 8126
Gaithersburg, MD 20898-8126
For a Complete Report
This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.
The information provided in this report is not intended for diagnostic purposes. It is provided for informational purposes only. NORD recommends that affected individuals seek the advice or counsel of their own personal physicians.
It is possible that the title of this topic is not the name you selected. Please check the Synonyms listing to find the alternate name(s) and Disorder Subdivision(s) covered by this report
This disease entry is based upon medical information available through the date at the end of the topic. Since NORD's resources are limited, it is not possible to keep every entry in the Rare Disease Database completely current and accurate. Please check with the agencies listed in the Resources section for the most current information about this disorder.
For additional information and assistance about rare disorders, please contact the National Organization for Rare Disorders at P.O. Box 1968, Danbury, CT 06813-1968; phone (203) 744-0100; web site www.rarediseases.org or email firstname.lastname@example.org
Last Updated: 7/1/2005
Copyright 1986, 1989, 1994, 1997, 2005 National Organization for Rare Disorders, Inc.
Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.